Driving discovery
through clinical trials

The world’s most extensive program of in-human NMN research.

We are advancing a broad and diverse pipeline of small molecule therapies to address significant health- and lifespan associated conditions, and to develop treatment options for some of the most prevalent age-associated conditions and diseases.

Our pipeline is comprised of multiple preclinical and clinical-stage therapeutic candidates that have the potential to deliver optimal benefits while maintaining a strong safety profile.

  Study design Expected completion date
Skin anti-aging 40 participants - 28 days - 5% nmn creamCompleted
Skin health 60 participants - 56 days - 2% nmn creamCompleted
Physical capacity and muscle recovery 150 participants - 38 days - placebo/NMN 250mg/NMN 500mgOngoing
Tolerance & NAD+ levels 20 participants - 30 days - NMN 400mgCompleted
Pharmacokinetics 24 participants - 30 days - NMN 400mg Q4 2022
Lipid and glucose management 80 participants - 120 days - placebo/NMN 800m Q3 2022
Senior healthspan extension NMN vs NR 200 participants - 360 days - placebo/NMN 750mg Q4 2022
Immune health 200 participants - 120 days - placebo/NMN 600mg Q3 2022